C12N 2710/10141
Use of virus, viral particle or viral elements as a vector
C12N2710/10141 (Use of virus, viral particle or viral elements as a vector) appears on 7 US grants and 13 published applications in this corpus.
Search patents in C12N- Granted patents
- 7
- Published applications
- 13
- Assignees
- 10
- Inventors
- 32
- Latest grant
- 11 Nov 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 1 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 0 |
| 2017 | 1 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 1 |
| 2020 | 0 | 1 |
| 2021 | 0 | 0 |
| 2022 | 0 | 0 |
| 2023 | 2 | 1 |
| 2024 | 0 | 1 |
| 2025 | 1 | 1 |
By publication year.
Subgroups
Granted patents
- C12N 2710/10143Viral genome or elements thereof as genetic vectorIndexing code4
- C12N 2710/10142Virus or viral particle as vehicleIndexing code0
- C12N 2710/10144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code0
- C12N 2710/10145Special targeting system for viral vectorsIndexing code0
Recent patents
- Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism11 Nov 2025US 12,467,065 B2The Board of Trustees of the Leland Stanford Junior University
- Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism21 Mar 2023US 11,608,510 B2The Board of Trustees of the Leland Stanford Junior University
- Formulation28 Feb 2023US 11,590,243 B2Glaxosmithkline Biologicals SA
- Replicating recombinant adenovirus vectors, compositions, and methods of use thereof5 Sep 2017US 9,750,801 B2Beth Israel Deaconess Medical Center, Inc.
- Adenoviral-based vectors21 Oct 2014US 8,865,182 B2Paxvax, Inc.
- Adenovirus delivery system for cancer treatment16 Jan 2025US 2025/0018060 A1Christiana Care Gene Editing Institute, Inc.
- Method and composition for treating non-alcoholic fatty liver disease, associated conditions and symptoms22 Feb 2024US 2024/0060072 A1The Hong Kong Polytechnic University
- Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism28 Sep 2023US 2023/0304039 A1The Board of Trustees of the Leland Stanford Junior University
- Novel recombinant adeno-associated virus capsids with enhanced human pancreatic tropism23 Jan 2020US 2020/0024616 A1The Board of Trustees of the Leland Stanford Junior University
- Novel formulation5 Dec 2019US 2019/0365930 A1Glaxosmithkline Biologicals SA
Most cited
By later US patents
- DNA encoding ovine adenovirus (OAV287) and its use as a viral vector21US 7,037,712 B2Commonwealth Scientific and Industrial Research Organisation · 2006
- Adenoviral-based vectors13US 8,865,182 B2Paxvax, Inc. · 2014
- Replicating recombinant adenovirus vectors, compositions, and methods of use thereof9US 9,750,801 B2Beth Israel Deaconess Medical Center, Inc. · 2017
- Recombinant adeno-associated virus capsids with enhanced human pancreatic tropism1US 11,608,510 B2The Board of Trustees of the Leland Stanford Junior University · 2023